10.39
-1.63 (-13.56%)
| Penutupan Terdahulu | 12.02 |
| Buka | 11.24 |
| Jumlah Dagangan | 5,313,867 |
| Purata Dagangan (3B) | 2,702,160 |
| Modal Pasaran | 1,058,211,136 |
| Harga / Jualan (P/S) | 22.73 |
| Harga / Buku (P/B) | 1.08 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Feb 2025 - 24 Feb 2025 |
| Margin Operasi (TTM) | -1,588.96% |
| EPS Cair (TTM) | -5.45 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -24.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.56% |
| Nisbah Semasa (MRQ) | 6.73 |
| Aliran Tunai Operasi (OCF TTM) | -356.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -184.96 M |
| Pulangan Atas Aset (ROA TTM) | -27.81% |
| Pulangan Atas Ekuiti (ROE TTM) | -52.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Intellia Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.20 |
|
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.19% |
| % Dimiliki oleh Institusi | 92.07% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Casdin Capital, Llc | 30 Sep 2024 | 2,000,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 91.00 (Chardan Capital, 775.84%) | Beli |
| Median | 45.00 (333.11%) | |
| Rendah | 12.00 (Goldman Sachs, 15.50%) | Pegang |
| Purata | 44.90 (332.15%) | |
| Jumlah | 6 Beli, 4 Pegang | |
| Harga Purata @ Panggilan | 13.09 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 14 Jan 2025 | 12.00 (15.50%) | Pegang | 9.70 |
| 25 Oct 2024 | 20.00 (92.49%) | Pegang | 15.95 | |
| Oppenheimer | 13 Jan 2025 | 40.00 (284.99%) | Beli | 9.70 |
| 11 Nov 2024 | 60.00 (477.48%) | Beli | 17.50 | |
| BMO Capital | 10 Jan 2025 | 50.00 (381.23%) | Beli | 10.20 |
| Wells Fargo | 10 Jan 2025 | 60.00 (477.48%) | Beli | 10.20 |
| 18 Nov 2024 | 70.00 (573.72%) | Beli | 14.17 | |
| Canaccord Genuity | 19 Nov 2024 | 90.00 (766.22%) | Beli | 14.13 |
| Chardan Capital | 18 Nov 2024 | 91.00 (775.84%) | Beli | 14.17 |
| 24 Oct 2024 | 88.00 (746.97%) | Beli | 15.85 | |
| Wedbush | 18 Nov 2024 | 14.00 (34.74%) | Pegang | 14.17 |
| Barclays | 08 Nov 2024 | 55.00 (429.36%) | Beli | 16.73 |
| Baird | 25 Oct 2024 | 18.00 (73.24%) | Pegang | 15.95 |
| Citigroup | 25 Oct 2024 | 19.00 (82.87%) | Pegang | 15.95 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BASTA JAMES | - | 12.13 | -7,074 | -85,808 |
| CLARK ELIANA | - | 12.18 | -7,978 | -96,823 |
| DUBE MICHAEL P | - | 12.13 | -1,372 | -16,642 |
| HICKS DEREK | - | 12.13 | -6,502 | -78,869 |
| LEBWOHL DAVID | - | 12.13 | -9,557 | -115,926 |
| LEONARD JOHN M | - | 12.13 | -26,807 | -325,169 |
| SEPP-LORENZINO LAURA | - | 12.13 | -8,966 | -108,758 |
| Jumlah Keseluruhan Kuantiti Bersih | -68,256 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -827,995 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 12.14 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CLARK ELIANA | Pegawai | 03 Jan 2025 | Jual (-) | 7,422 | 12.13 | 90,029 |
| SEPP-LORENZINO LAURA | Pegawai | 03 Jan 2025 | Jual (-) | 8,966 | 12.13 | 108,758 |
| LEONARD JOHN M | Pegawai | 03 Jan 2025 | Jual (-) | 26,807 | 12.13 | 325,169 |
| LEBWOHL DAVID | Pegawai | 03 Jan 2025 | Jual (-) | 9,557 | 12.13 | 115,926 |
| HICKS DEREK | Pegawai | 03 Jan 2025 | Jual (-) | 6,502 | 12.13 | 78,869 |
| BASTA JAMES | Pegawai | 03 Jan 2025 | Jual (-) | 7,074 | 12.13 | 85,808 |
| DUBE MICHAEL P | Pegawai | 03 Jan 2025 | Jual (-) | 1,372 | 12.13 | 16,642 |
| CLARK ELIANA | Pegawai | 02 Jan 2025 | Jual (-) | 556 | 12.22 | 6,794 |
| SEPP-LORENZINO LAURA | Pegawai | 01 Jan 2025 | Pelaksanaan pilihan | 3,500 | - | - |
| LEBWOHL DAVID | Pegawai | 01 Jan 2025 | Pelaksanaan pilihan | 3,189 | - | - |
| LEONARD JOHN M | Pegawai | 01 Jan 2025 | Pelaksanaan pilihan | 7,850 | - | - |
| Papar semua | ||||||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |